Business Wire

NY-SERMO

1.12.2022 15:06:35 CET | Business Wire | Press release

Share
Sermo Survey Finds Opportunity to Educate General Care Physicians on PrEP to Increase Patient Adoption

Timed to World AIDS Day, Sermo, a physician-first online community and leader in global HCP insights, released a new survey that found 46% of general care physicians including PCPs, OB-GYNs, and pediatric physicians, reported they feel they do not have enough knowledge about currently approved PrEP medication options to prescribe them to patients. Whereas 98% of infectious disease specialists reported they felt they have enough knowledge about PrEP medications signaling a need for further education from industry stakeholders for noninfectious disease specialists. An important area of opportunity as patients who are likely good candidates for PrEP often go to a PCP instead of seeking out an infectious disease specialist.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005355/en/

The cost of PrEP continues to be a driving factor for patients’ decision to decline treatment in the U.S. as reported by 26% of surveyed physicians. However, PrEP is fully covered in most instances when a patient has private insurance, highlighting another opportunity to further educate patients and providers via patient support and financial assistance programs. Despite PrEP private insurance coverage, young adults 26 years old and under face insurance barriers to accessing PrEP. 23% of surveyed physicians said they don’t know of any resources to help patients on their parent's insurance who want to access PrEP but don’t want their parents to find out. This number declined to 16% when surveying just infectious disease specialists, suggesting an area of opportunity for wider outreach among patient support and financial assistance programs to help this patient population.

Concerns about the cost being the driving factor for patients declining PrEP are lower in Europe than in the U.S. When comparing physician experiences, cost was the number one driver of patients declining PrEP treatment compared to the number three reason in the EU5. The rest of the world followed the U.S. sentiment of cost being the leading reason patients decline PrEP. In Europe, physicians reported the top reason patients declined PrEP treatment is planning to take other preventative measures (27%), followed by stigma (24%), and then cost (20%).

PrEP Adoption Faces Challenges on Multiple Fronts Beyond Cost and Education:

  • PrEP isn’t top-of-mind for most patients: only 16% of surveyed physicians reported that patients often proactively asked them for PrEP.
  • Patients struggle to maintain adherence to PrEP: 70% of surveyed physicians reported that patients often or sometimes have a hard time adhering to the once-a-day pill schedule of taking PrEP.
  • Misinformation about how PrEP works persists as 49% of surveyed physicians reported hearing misinformation about the treatment from patients in their practices.
  • When asked the most common misinformation they hear in their practices, PrEP is only for men who have sex with other men is what they heard most often as reported by 63% of physicians. This is in contradiction with the reality that an average of 22% of new HIV diagnoses each year are from heterosexual contact.

“HIV is 100% preventable. Education for both providers and patients is critical in making more progress against the HIV/AIDS epidemic,” says Dr. Claudia Martorell, an Infectious Disease Specialist and Sermo Medical Advisory Board Member. “Education, along with improved insurance coverage, increased medication awareness, better access for at-risk populations, and decreasing stigma around HIV infection all support our ability to do a better job in ending the epidemic.”

Cost & Adherence Keep HIV Patients From Successful Treatment Regiments:
Similar to concerns about the cost of PrEP, affordability is the key treatment attribute that is most important to physicians when recommending an HIV medication to a patient (17%) followed by fewer side effects (15%), and less medication to take each day (13%). In addition, physicians reported adherence is another key barrier to HIV treatment as more than half (56%) of physicians reported that patients they are treating for HIV/AIDS have a difficult time following a strict medication adherence program. Interest in longer-lasting injectable medications is likely to be high among HIV patients, as 48% of surveyed physicians reported that patients simply forgetting to take their medication is the top reason patients didn’t adhere to treatment plans. Multidrug-resistant HIV is also a huge concern for physicians as nearly half (43%) reported treating patients with these issues.

This survey was fielded as part of Sermo’s ongoing Barometer survey. The survey included more than 600 global physicians who were surveyed between November 2nd - 14th, 2022. To explore more findings, visit app.sermo.com/barometer.

About Sermo:
Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005355/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 01:00:00 CET | Press release

Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa

UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release

Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye